Check out which companies are making headlines before the bell:
Hospira–The injectable drug maker will be acquired by Pfizer for $90 per share in cash, a total of about $16 billion. The deal represents a nearly 39 percent premium to Hospira's Wednesday closing price. Pfizer said the deal will add 10 to 12 cents per share to earnings in the first year.
L Brands–The Victoria's Secret parent raised its quarterly dividend by 47 percent to $2.00 per share, announced a special dividend of $2.00 per share, raised its fourth quarter earnings guidance, and saw January and comparable store sales come in above estimates.
Michael Kors–The luxury goods maker beat estimates by 15 cents with quarterly profit of $1.48 per share, with revenue above estimates as well. However, the company also gave earnings and revenue guidance for the current quarter that falls below Street estimates.
Cigna–The insurer reported quarterly profit of $1.69 per share, beating estimates by two cents, with revenue also above consensus. The results were helped by an increase in premiums, and cost management moves.
Becton Dickinson–The maker of medical products came in 10 cents above estimates with adjusted quarterly profit of $1.53 per share. Revenue also came in above analyst forecasts, and the company raised its revenue forecast for the full year as well.
Sirius XM–The satellite radio operator earned three cents per share for its latest quarter, beating estimates by one cent. Revenue was also above analyst forecasts, and fourth quarter subscriber additions represented the highest year-end number since 2007.
Dunkin' Brands–The coffee and donut chain reported adjusted quarterly profit of 46 cents per share, missing estimates by one cent. The company also raised its quarterly dividend to 26.5 cents per share from 23 cents. Dunkin' cut its full-year outlook because of sluggish fourth quarter sales growth.
Weatherford International–The oilfield services company is cutting 5,000 jobs in response to the sharp drop in crude oil prices.
Keurig Green Mountain-The maker of single-brew coffee systems missed estimates by a penny with adjusted quarterly profit of 88 cents per share. Revenue was also below estimates and the company gave disappointing guidance for the current fiscal year following lower-than-expected holiday season sales.
Yum Brands–Yum earned an adjusted 61 cents per share for its latest quarter, missing estimates by five cents, although revenue did come in above forecasts. The parent of KFC, Taco Bell, and Pizza hut also saw same-store sales fall by 16 percent in its key China market, but that drop was less than analysts had predicted.
21st Century Fox–Fox reported adjusted quarterly profit of 53 cents per share, 12 cents above estimates, with revenue also beating projections. Additionally, Fox increased its quarterly dividend by 20 percent. However, the company also cut its profit guidance for the full year due to the impact of a stronger dollar and a shift in its viewer and advertising mix.
Under Armour–Under Armour beat estimates by one cent with quarterly profit of 40 cents per share, with revenue above consensus as well. The maker of athletic apparel also bought fitness app MyFitnessPal for $475 million.
Allergan–Allergan reported adjusted quarterly profit of $2.17 per share, 34 cents above estimates, with revenue slightly ahead of consensus forecasts. The drug maker was helped by double-digit sales increases, ahead of its pending acquisition by Actavis.
Harley-Davidson–The motorcycle maker raised its cash dividend by 13 percent to 31 cents per share, payable March 6 to shareholders of record on February 18. It also named President/COO Matt Levatich as its new chief executive officer effective May 1, when current CEO Keith Wandell retires.
Netflix–The video service announced it will enter the Japan market in the fall of this year.
Caesars Entertainment–The hotel and casino operator named former Hertz CEO Mark Frissora as its new CEO, effective July 1, replacing current CEO Gary Loveman.
CME Group–The exchange operator will shut down most of its open-outcry futures trading pits by July 2, reflecting the surge in computerized trading.
AstraZeneca–The drug maker will buy the branded lung drug business of Actavis for $600 million. The deal came alongside news that AstraZeneca's latest quarterly profit fell short of analyst estimates.
CBS–CEO Les Moonves is seeking to buy out the controlling stake in the company currently held by National Amusements, according to the New York Post.